Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

  • There is currently no data for N4P

Trading update

21 Mar 2011 07:00

RNS Number : 2659D
Ultima Networks PLC
21 March 2011
 



Embargoed for release at 7am 21 March 2011

 

Ultima Networks plc

('Ultima' or the 'Company')

 

Trading update

 

 

Ultima, the IT and Green Technology company, is pleased to provide an update on trading in advance of the release of its results for the year ended 31 December 2010.

 

Ultima is please to announce that full year revenues and net profit have increased over the prior year. The Board expects to report turnover to be broadly in line with market expectations with net profit being materially ahead of market expectations.

 

Ultima's IT Services division, Cognito Software, has continued to grow through increased sales of its range of software products and services. Following the launch of "FiLos", Cognito's new legal software suite, Ultima has seen an increased level of interest in Cognito's product offering particularly from the larger legal practices. The sales, support and marketing budget for Cognito during 2011 has been increased with the view to accelerating the organic growth of the division primarily through increased penetration of FiLos in the legal services marketplace. The Board is also continuing to evaluate potential acquisitions which would assist the growth of the division. The IT Services division provides recurring revenue for Ultima and is benefiting from a strong management team.

 

The Company's Green technology products division experienced difficult market conditions in the first half of 2010, as announced by Ultima on 19 August 2010. The Board of Ultima is pleased to however report that the second half of the year has seen an improved trading performance and, as previously announced, Ultima has in the second half of the year received major new orders for its mainland European version of the Infineum electric bicycle. The level of these orders has exceeded management expectations. The Board remain confident that volumes for the 2011 calendar year will reach the division's targets of 2,500 units. The bicycle is being marketed by the division's Dutch distributor, EQ-Bikes.

 

Ultima's Green power division, which is focused on the development of clean power generation through solar power parks in Spain and Italy, continued to develop its solar energy credentials in 2010. In November 2010 Ultima successfully commissioned and connected the Company's 100KW solar park in Spain to the Spanish National Grid. This is expected to make a small contribution to Ultima's revenue in 2011. In Italy discussions are continuing with ENEL Spa to finalise details for the connection to the Italian high voltage grid however no connection date has yet been given by ENEL and Ultima are currently considering alternative options to generate value from their Italian solar power project. The Board remain in discussions with potential parties who are interested in providing debt funding to support the construction of the proposed three 1MW Solar Parks planned for Puglia. Delays in connection of the proposed 3 x 1 MW parks will lead to a reduction in the feed-in tariff however the Board expects this to be offset by reductions in the capital cost of the projects. The Green power division has also recently launched a Solar PV Initative Scheme for UK based Schools which is designed to provide solar installations to participating schools free of cost. The Green power division will receive the government backed feed-in tariff which is index linked and guaranteed to be paid for a period of 25 years.

 

Ultima anticipates releasing its results for the year ended 31 December 2010 on 23rd May 2011.

 

 

Ultima Networks plc

Prof. Humayun Mughal, Chairman and CEO

Tel: 01279 821 200

Allenby Capital Limited

(Nominated Adviser and Broker)

Tel: +44 (0)203 328 5656

Nick Naylor

Nick Athanas

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSFIFWAFFSEDD
Date   Source Headline
17th Mar 202612:14 pmRNSResult of General Meeting and Change of Name
27th Feb 20267:00 amRNSNotice of GM and Proposed Change of Name
24th Feb 20267:00 amRNSCEO Appointment & Name Change Thalia Therapeutics
17th Dec 20257:00 amRNSBusiness and Operational Update
25th Sep 20257:00 amRNSInterim Results
23rd Sep 20257:00 amRNSPartnership with University of Strathclyde’s CMAC
22nd Sep 20257:00 amRNSN4 Pharma’s Nuvec® Targets Lung Cancer Cells
19th Sep 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
11th Sep 20257:00 amRNS-RInvestor Event and Presentation
30th Jul 20251:55 pmRNS-RArticle on Nuvec®’s Potential in RNA Therapeutics
14th Jul 20257:00 amRNS-RInvestor Webinar
8th Jul 20257:00 amRNSDirectorate Change
30th Jun 20252:15 pmRNSResult of AGM
30th Jun 20257:00 amRNSAGM Statement
25th Jun 20257:00 amRNS-RInsight Event for Retail Investors
6th Jun 20257:00 amRNSFinal Results, Annual Report and Notice of AGM
27th May 20257:00 amRNS-REstablishment of New Senior Leadership Team
23rd May 202512:37 pmRNSTR-1: Notification of major holdings
21st May 20254:11 pmRNSHolding(s) in Company
15th May 20253:13 pmRNSChange of Registered Address
12th May 20257:00 amRNSN4 101 In Vivo Study Results
9th May 20258:24 amRNSHolding(s) in Company
29th Apr 20254:25 pmRNSHolding(s) in Company
29th Apr 202511:05 amRNSHolding(s) in Company
28th Apr 20252:30 pmRNSHolding(s) in Company
23rd Apr 20252:32 pmRNSTR-1: Standard form notification of major holdings
22nd Apr 202511:56 amRNSResult of General Meeting
4th Apr 20257:08 amRNSPosting of Circular and Notice of General Meeting
1st Apr 20254:08 pmRNSPlacing and Subscription to raise £1,750,000
18th Feb 202512:34 pmRNSHolding(s) in Company
7th Feb 20257:00 amRNS-RInvestor Webinar
27th Jan 20257:00 amRNS-RInvestor Webinar
16th Jan 20257:00 amRNS-RN4 Pharma Non-Executive Director Q&A
8th Jan 20257:00 amRNSDirectorate Changes
12th Dec 20247:00 amRNSN4 101 In Vitro Results
4th Dec 20247:00 amRNSNew Patent Filing
28th Nov 20247:00 amRNSGrant of Options
24th Sep 20247:00 amRNSInterim Results
17th Sep 20248:04 amRNSSRI Research Update
9th Sep 20247:00 amRNSDirector Appointment
23rd Aug 20248:30 amRNSChange of Auditor
20th Aug 20247:00 amRNSSRI Research Update
3rd Jul 20247:00 amRNSNanogenics Update
28th Jun 20247:00 amRNSTotal Voting Rights
19th Jun 20247:00 amRNSHolding(s) in Company
18th Jun 202412:34 pmRNSHolding(s) in Company
13th Jun 20244:52 pmRNSHolding(s) in Company
11th Jun 202411:16 amRNSNew Corporate Presentation
7th Jun 202410:18 amRNSPlacing and Subscription to raise £630,000
23rd May 20244:09 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.